## 1) VALUE (250 words)
For a person at home asking about their own supplements and medicines, this service does not yet deliver a durable advantage over a strong model with web search. The best internal evidence is that web-only runs already surface most major hazards and often broader context (`evidence/cabinets/web_only/cabinet_a_model_a.md`, `evidence/cabinets/web_only/cabinet_b_and_c_model_a.md`). The lookup-added runs do contribute something real: source-grounded snippets, explicit provenance structure, and explicit uncertainty states like “no record” and “not checked” (`evidence/cabinets/lookup_files/cabinet_a.yaml`, `evidence/cabinets/lookup_files/cabinet_b.yaml`, `evidence/cabinets/lookup_files/cabinet_c.yaml`).

But the misses are structural and directly user-harmful for home use: no records for ashwagandha/fish oil, berberine/chromium, melatonin/CBD; and no medicine-medicine checking (`not_checked`) even when a known high-impact Rx-Rx interaction exists (`evidence/cabinets/lookup_files/cabinet_a.yaml`, `evidence/cabinets/lookup_files/cabinet_b.yaml`, `evidence/cabinets/lookup_files/cabinet_c.yaml`). That means “nothing found” can be interpreted as safety when it is really coverage failure.

I also see wide model behavior variance: one run is careful and bounded, others are overconfident or partially unsourced (`evidence/cabinets/web_plus_lookup/model_e.md` vs `evidence/cabinets/web_plus_lookup/model_c.md` and `evidence/cabinets/web_only/cabinet_a_model_c.md`).

External search confirms crowded substitutes already exist for consumers and professionals (Drugs.com, Medscape, NatMed, Lexidrug, Micromedex).

Scorecards judgment: `SCORECARDS.md` is absent in this folder, so I cannot test its exact claims. Based on available evidence, any claim of clear consumer differentiation is likely overstated; any claim that provenance/auditability is valuable for regulated workflows is likely understated.

## 2) STOP OR CONTINUE (300 words)
Strongest case for stopping: this is not a product, it is a partially built substrate wrapped in a consumer promise. The unresolved basics are exactly where trust breaks: automated product-to-ingredient resolution is unproven, cross-product totals are unproven, software matching is unproven, ingredient authoring cost is unknown, key common supplements are missing, and Rx-Rx interactions are explicitly out of scope (`evidence/cabinets/lookup_files/cabinet_a.yaml`, `evidence/cabinets/lookup_files/cabinet_b.yaml`, `evidence/cabinets/lookup_files/cabinet_c.yaml`). In a safety-adjacent domain, partial coverage plus confident prose is worse than no tool. You also face incumbents with distribution, legal infrastructure, and existing payer budgets. If your go-to-market is “safer answers for people at home,” current evidence does not support that claim. Continuing on the current trajectory likely converts technical debt into liability debt.

Strongest case for continuing: there is one nontrivial asset here that many AI wrappers do not have—statement-level source grounding that can be audited and potentially enforced at generation time (`evidence/single_questions/lookup_slices/q1.yaml`, `evidence/single_questions/lookup_slices/q3.yaml`, `evidence/single_questions/whole_records/model_c.md`). That matters more in enterprise settings than consumer chat. The lookup corpus also encodes regulatory language and conditional warnings in a machine-usable form, not just free text (`evidence/cabinets/lookup_files/cabinet_a.yaml`, `evidence/cabinets/lookup_files/cabinet_b.yaml`, `evidence/cabinets/lookup_files/cabinet_c.yaml`). If you pivot from “advice service” to “evidence infrastructure + explainable CDS component,” you could sell a narrower, defensible capability: provenance-backed interaction evidence and abstention metadata. In other words: stop trying to be the final advisor; continue by becoming the reliability layer others embed.

## 3) WHO IT IS FOR (350 words)
The two most plausible buyers are (1) pharmacy/health-system software teams and (2) builders of health apps/AI agents.

For pharmacy or health systems, the usable unit is not a chat answer; it is an auditable evidence object: interaction statement, source excerpt, evidence type, confidence, and explicit non-coverage flags. They would pay for reduced review time, better documentation, and safer intervention workflows (especially where supplement use is under-captured). What is missing: complete coverage of commonly used supplements; reliable Rx-Rx checking or clear integration path to existing drug databases; deterministic product-ingredient normalization; ongoing update operations; and prospective validation against pharmacist adjudication. Without those, this is not deployment-grade despite good provenance scaffolding (`evidence/cabinets/lookup_files/cabinet_a.yaml`, `evidence/cabinets/lookup_files/cabinet_b.yaml`, `evidence/cabinets/lookup_files/cabinet_c.yaml`).

For builders of health apps/agents, the value is a grounding API that constrains generation and logs “why this claim was made.” They would pay per check, per member, or via compliance tiering if it materially lowers hallucination and review burden. What is missing: robust abstention policy, latency/SLA guarantees, conflict-resolution logic when sources disagree, and governance around stale citations. Today’s behavior variance across models suggests the reliability envelope is not yet tight enough (`evidence/cabinets/web_plus_lookup/model_e.md`, `evidence/cabinets/web_plus_lookup/model_c.md`, `evidence/cabinets/web_only/cabinet_a_model_c.md`).

Is some built component worth more used another way than the service as designed? Yes. The records, extraction schema, and “stored statement matches source” pattern are likely more valuable as infrastructure than as a direct consumer advice product. The strongest monetizable core is an explainability/provenance layer for third-party CDS and agent systems, not a standalone “tell me if my stack is safe” app.

## 4) AGENTS (200 words)
Yes, evidence suggests an agent needs this type of substrate more than a person does—if the substrate is complete and machine-enforceable. A person can ask a web-enabled model and sanity-check with a pharmacist. An autonomous or semi-autonomous agent cannot safely improvise in a high-consequence domain; it needs grounded claims, explicit abstention, and machine-readable uncertainty. The lookup format already hints at that direction (`evidence/single_questions/lookup_slices/q3.yaml`, `evidence/single_questions/whole_records/model_c.md`).

What would have to be true:
1) coverage is broad enough that “nothing found” usually means low risk, not database gap;
2) product resolution and dose aggregation are automated and validated;
3) software matching, conflict handling, and update cadence are operationalized;
4) every recommendation carries provenance, confidence, and a fail-closed path;
5) the agent is constrained to escalation rather than autonomous treatment decisions.

Without those conditions, agents amplify the downside. They make errors faster, with more authority, and at larger scale.

## 5) LAW AND LIABILITY (250 words)
Not legal advice.

Likely higher-risk uses:
- Consumer-facing patient-specific treatment recommendations (“take/stop/change this regimen now”) are the riskiest. In the U.S., FDA CDS boundaries depend on whether an HCP can independently review basis and not primarily rely on output; direct-to-consumer advice weakens that posture.
- Any workflow that meaningfully directs diagnosis/treatment could trigger device treatment (FDA CDS framework in U.S.; Rule 11 classifications in EU MDR, often Class IIa and potentially higher for severe-impact decisions).
- “Nothing found” when wrong creates foreseeable negligence and deceptive-practice exposure, especially where coverage gaps are known and not made salient.
- If marketed with efficacy/safety claims beyond evidence, FTC-style substantiation and omission risk appears immediate.

Practice-of-medicine/pharmacy risk: state counseling frameworks generally treat digital content as support to professional counseling, not a replacement. If the service is positioned as substituting pharmacist/clinician judgment, risk increases.

Safest uses:
- Internal evidence browser for clinicians/pharmacists.
- Documentation/provenance support layer for existing professional CDS.
- Drafting aid that always routes final patient advice to licensed professionals.

What I searched: FDA CDS guidance and FAQs; EU MDR software qualification/classification guidance (MDCG Rule 11 materials); ONC HTI-1 DSI source-attribute requirements; existing interaction products (Drugs.com, Medscape, NatMed, Lexidrug, Micromedex); pharmacy counseling duty materials and case-law summaries; FTC health-products substantiation guidance.

## 6) VERDICT (150 words)
Change direction.

Do not continue as a consumer advice service. Do not fully stop either. Pivot to a B2B evidence and provenance component for clinical/pharmacy workflows and regulated health-app builders.

One result that would change my mind: a blinded, prospective test showing that end-to-end automated operation (real product parsing, ingredient resolution, dose totals across products, software matching, and one new ingredient authoring) materially beats a strong web-enabled model baseline on clinically significant interaction recall while reducing unsupported claims.

Cheapest test: 100 real de-identified supplement+medication lists from retail pharmacy or ambulatory intake forms; dual pharmacist gold-standard adjudication; compare (a) strong web model, (b) your current pipeline, (c) your pipeline with strict abstention. Primary endpoint: sensitivity on major interactions. Secondary: unsafe false reassurance rate from “nothing found,” time-to-answer, and authoring cost per new ingredient.

## 7) WHAT THIS PACKET GETS WRONG (150 words)
It frames the project like a near-term service when the evidence mostly supports a mid-layer capability.

It omits critical artifacts: `BRIEF.md` and `SCORECARDS.md` are not present in the provided folder, which blocks direct verification of sponsor claims. It emphasizes answer examples but underweights operations evidence: coverage completeness, update latency, mapping error rates, and adjudicated accuracy.

It also allows favorable framing through synthetic cases where the hardest production problems are deferred: branded product normalization, multi-product total dosing, and robust abstention behavior. The packet repeatedly shows “no record” and “not checked” states on common items yet does not quantify how often those states would appear in real traffic (`evidence/cabinets/lookup_files/cabinet_a.yaml`, `evidence/cabinets/lookup_files/cabinet_b.yaml`, `evidence/cabinets/lookup_files/cabinet_c.yaml`).

Most importantly, it under-models downside economics: in this category, one confident false negative can erase a long run of correct outputs.
